GeoVax Labs Inc Cash Flow Conversion Efficiency
GeoVax Labs Inc cash flow conversion efficiency. Based on the latest financial reports, GeoVax Labs Inc (GOVX) has a cash flow conversion efficiency ratio of -1.266x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.21 Million) by net assets ($4.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of GeoVax Labs Inc (1996–2024)
Cash flow conversion efficiency of GeoVax Labs Inc from 1996 to 2024. This chart illustrates how GeoVax Labs Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GOVX share price today for real-time trading data and today's change.
GeoVax Labs Inc Cash Flow Conversion Ratio Explained
GeoVax Labs Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
GeoVax Labs Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeoVax Labs Inc ranked by their cash flow conversion efficiency. Also see GeoVax Labs Inc (GOVX) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shoe Zone PLC
LSE:SHOE
|
0.326x |
|
Global Gas Corporation
NASDAQ:HGAS
|
0.072x |
|
Arecor Therapeutics PLC
LSE:AREC
|
-0.178x |
|
SU Group Holdings Limited Ordinary Shares
NASDAQ:SUGP
|
-0.057x |
|
PROPHECY DEFI INC.
F:V8M
|
N/A |
|
ALBERT LABS INTL. CORP.
F:VB50
|
N/A |
|
Medivie Therapeutic Ltd
TA:MDVI
|
0.217x |
|
Profusa, Inc. Common Stock
NASDAQ:PFSA
|
0.091x |
Annual Cash Flow Conversion Efficiency for GeoVax Labs Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of GeoVax Labs Inc from 1996 to 2024. Review GeoVax Labs Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.05 Million | $-24.68 Million | -4.888x | -11.90% |
| 2023-12-31 | $5.76 Million | $-25.17 Million | -4.368x | -510.53% |
| 2022-12-31 | $26.60 Million | $-19.03 Million | -0.715x | +72.13% |
| 2021-12-31 | $4.36 Million | $-11.20 Million | -2.567x | -792.97% |
| 2020-12-31 | $9.57 Million | $-2.75 Million | -0.287x | -132.36% |
| 2019-12-31 | $-1.57 Million | $-1.40 Million | 0.888x | -41.17% |
| 2018-12-31 | $-1.02 Million | $-1.54 Million | 1.510x | -71.29% |
| 2017-12-31 | $-321.06K | $-1.69 Million | 5.259x | +164.96% |
| 2016-12-31 | $240.37K | $-1.95 Million | -8.096x | -260.52% |
| 2015-12-31 | $1.20 Million | $-2.71 Million | -2.246x | -14.40% |
| 2014-12-31 | $1.15 Million | $-2.25 Million | -1.963x | -192.77% |
| 2013-12-31 | $2.53 Million | $-1.69 Million | -0.671x | +68.39% |
| 2012-12-31 | $1.15 Million | $-2.44 Million | -2.121x | -391.54% |
| 2011-12-31 | $703.61K | $-303.62K | -0.432x | +60.52% |
| 2010-12-31 | $1.84 Million | $-2.01 Million | -1.093x | -187.18% |
| 2009-12-31 | $3.74 Million | $-1.43 Million | -0.381x | +56.44% |
| 2008-12-31 | $2.71 Million | $-2.37 Million | -0.874x | +29.15% |
| 2007-12-31 | $2.65 Million | $-3.27 Million | -1.233x | -104.63% |
| 2006-12-31 | $2.20 Million | $-1.33 Million | -0.603x | -341.49% |
| 2005-12-31 | $-5.72 Million | $-1.43 Million | 0.250x | -0.01% |
| 2004-12-31 | $-4.95 Million | $-1.23 Million | 0.250x | +430.50% |
| 2003-12-31 | $-3.82 Million | $288.31K | -0.076x | +96.33% |
| 2001-12-31 | $2.05 Million | $-4.21 Million | -2.056x | -241.90% |
| 2000-12-31 | $10.52 Million | $-6.33 Million | -0.601x | +92.55% |
| 1999-12-31 | $552.34K | $-4.46 Million | -8.070x | -335.13% |
| 1998-12-31 | $2.89 Million | $-5.35 Million | -1.855x | -330.19% |
| 1997-12-31 | $5.68 Million | $-2.45 Million | -0.431x | -14.43% |
| 1996-12-31 | $3.09 Million | $-1.17 Million | -0.377x | -- |
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marb… Read more